News & events
Press Releases
June 14, 2022
NCI/NIH Award $2 Million to Immunicom to Initiate Clinical Trial Evaluating Breakthrough Immunopheresis® LW-02 Molecular Subtractive Therapy in Refractory ER+/Her2- Breast Cancer
June 2, 2022
Immunicom Clinical Trial Data at ASCO 2022 Show Immunopheresis® LW-02 Column Safe and Effectively Depletes Soluble TNF-α Receptors in Patients with Advanced Triple Negative Breast Cancer
April 28, 2022
Immunicom Presents New Data at AACR 2022 of LW-02 Cartridge Immunopheresis® Therapy from Ongoing mTNBC Clinical Trial in Chemo-Refractory Patients
Get to Know Us
March 23, 2021
Breakthrough Immunotherapy Earns First Regulatory Approval for Triple Negative Breast Cancer (TNBC)
July 9, 2020
Unconventional Weapon in the War on Cancer Revealed
June 10, 2019
Immunicom Announces First Patient Enrollment in Multi-Center, Triple-Negative Breast Cancer Clinical Trial
May 14, 2018
Immunicom’s Immunotherapy Product Receives U.S. FDA Breakthrough Device Designation for the Treatment of Cancer
Get in touch today
Let’s talk about what we can achieve together
Learn more about
our team
our team